New Study suggests dermatologists completing a PI CME on psoriasis significantly improved in important patient care aspects. Learn more.
Can targeting differentially regulated proteins reverse or prevent disease?
The FDA announced Wednesday, January 21, that it approved secukinumab (Cosentyx, Novartis Pharmaceuticals Corporation) as a treatment for adults with moderate-to-severe plaque psoriasis.
Kevin D. Cooper, M.D., professor and chair of dermatology at Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, and Steven R. Feldman, M.D., Ph.D., professor of dermatology, Wake Forest University School of Medicine, Winston-Salem, N.C., weigh in on important gaps in dermatology research today.
A report published in January 2014 identified several gaps in psoriasis research and recommended research targets to address these gaps.
Getting patients to use their prescriptions is another story-one that's shockingly understudied in dermatology. Just what works to improve medication adherence has stumped researchers outside dermatology. Several studies are cited.
The antioxidant resveratrol inhibits Propionibacterium acnes growth. And when combined with benzoyl peroxide, resveratrol seems to enhance the acne drug’s bacteria-killing ability, according to results of a recent study.
The psychiatric comorbidities associated with psoriasis deserve more attention from physicians around the globe, experts say.
A patient with psoriasis asks dermatologists to put themselves in their patients' shoes and look at the condition from that perspective.
Richard D. Granstein, M.D., chairman of dermatology, Weill Cornell Medical College, New York, has conducted research on how the nervous system and, perhaps, stress can make psoriasis worse or control the phenotypic expression of psoriasis.